Intervacc

Stockholm, August 20, 2024 - Some of Europe's foremost strangles experts have compiled and published an article in which experiences from the use of Strangvac are discussed. The article was published in Equine Veterinary Education (EVE) which is the official journal for the education of practicing equine veterinarians through the organizations British Equine Veterinary Association (BEVA) and American Association of Equine Practitioners (AAEP). The magazine publishes peer reviewed articles on diagnostics and treatment of horses for equine veterinarians and veterinary students.

The purpose of the article is to share the experience gathered so far of the use of the vaccine in the field, as well as to provide guidelines for practicing veterinarians based on these experiences as vaccination is an important tool in the fight against strangles.

The article proposes recommendations regarding vaccination intervals and the authors review, among other things, the benefit of vaccination during ongoing strangles outbreaks, as the properties of the vaccine make it possible to differentiate infected from vaccinated animals, as well as the vaccination of pregnant mares and foals. The authors have also reviewed reported adverse events and make the assessment that the vaccine is safe to use.

Link to publication: https://beva.onlinelibrary.wiley.com/doi/10.1111/eve.14032

For more information please contact:  

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600, Cell: +46 (0) 70 576 30 73

E-mail: jonas.sohlman@intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on August 20, 2024, 13.15 p.m. CET.

About equine strangles

Equine strangles, caused by the bacterium Streptococcus equi, is a severe, common and highly contagious infectious disease that effect horses. Strangles is endemic in horse populations worldwide, with the exception of Iceland.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10